Claire Fong-McMaster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Claire Fong-McMaster has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Ariel Buchler
Department of Chemistry, University of Ottawa, Ottawa, Canada; University of Ottawa Heart Institute, Ottawa, Canada
1 shared publication - Ash Hagerman
Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
1 shared publication - Barbara C. Vanderhyden
Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada
1 shared publication - Benjamin H. Rotstein
Department of Chemistry, University of Ottawa, Ottawa, Canada; University of Ottawa Heart Institute, Ottawa, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada
1 shared publication - Carolina S. Ilkow
Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
1 shared publication - Christiano Tanese de Souza
Cancer Therapeutics Program, Ottawa Hospital Research Institute 1 , Ottawa, Canada
1 shared publication
Latest Publications
- Open Access
- 13 June 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (7)
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells. In line with these studies, here we show that engagement of PD-L1 via cellular ligands or agonistic antibodies, including those used in the clinic, potently inhibits the type I interferon pathway in cancer cells. Hampered type I interferon responses in PD-L1–expressing cancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo. Consistently, PD-L1 expression marked tumor explants from cancer patients that were best infected by oncolytic viruses. Mechanistically, PD-L1 promoted a metabolic shift characterized by enhanced glycolysis rate that resulted in increased lactate production. In turn, lactate inhibited type I IFN responses. In addition to adding mechanistic insight into PD-L1 intrinsic function, our results will also help guide the numerous ongoing efforts to combine PD-L1 antibodies with oncolytic virotherapy in clinical trials.
- 13 June 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (7)
Open AccessPD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells. In line with these studies, here we show that engagement of PD-L1 via cellular ligands or agonistic antibodies, including those used in the clinic, potently inhibits the type I interferon pathway in cancer cells. Hampered type I interferon responses in PD-L1–expressing cancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo. Consistently, PD-L1 expression marked tumor explants from cancer patients that were best infected by oncolytic viruses. Mechanistically, PD-L1 promoted a metabolic shift characterized by enhanced glycolysis rate that resulted in increased lactate production. In turn, lactate inhibited type I IFN responses. In addition to adding mechanistic insight into PD-L1 intrinsic function, our results will also help guide the numerous ongoing efforts to combine PD-L1 antibodies with oncolytic virotherapy in clinical trials.